Table 3.
Changes in the risk scores of metabolic syndrome over the SMESY intervention (N = 25,449).
| Time (Month) | High-Risk Group (n = 7116) | Moderate-Risk Group (n = 14,762) | Low-Risk Group (n = 3571) | |||
|---|---|---|---|---|---|---|
| Mean (SD) | p * | Mean (SD) | p * | Mean (SD) | p * | |
| Risk Score + | <0.001 | <0.001 | <0.001 | |||
| 0M | 0.63 (2.33) | −1.79 (0.28) | −6.72 (2.40) | |||
| 3M | −0.40 (2.39) a | - | - | |||
| 6M | −0.34 (2.43) b | −2.37 (2.36) b | - | |||
| 9M | −0.14 (2.35) c | - | - | |||
| 12M | −0.19 (2.30) d | −2.15 (2.29) d | −4.58 (2.37) d | |||
SD: Standard deviation; SMESY: Seoul Metabolic Syndrome Management; + Risk score indicates sum of standardized scores of mean arterial pressure, high-density lipoprotein cholesterol, triglycerides, waist circumference and fasting glucose created from subtracting the individual risk factor from the NHLBI/AHA criteria and dividing by the sample standard deviation; * p for linear trend using the linear mixed model after adjusting for age, gender, education, income, marital status, current smoking, physical activity, alcohol drinking, body mass index at baseline, and medications over 12 months; a p < 0.05: Significant difference between baseline and 3 months; b p < 0.05: significant difference between baseline and 6 months; c p < 0.05: Significant difference between baseline and 9 months; d p < 0.05: Significant difference between baseline and 12 months.